Role of quantitative bone scanning in the assessment of bone turnover in patients with Charcot foot.
OBJECTIVE
To assess the new quantitative bone scan parameters as markers of Charcot neuroosteoarthropathy (CNO) activity.


METHODS
Forty-two patients with acute (n = 21) and nonacute (n = 21) CNO underwent quantitative bone scanning. Patients with acute CNO were followed for 3-12 months and bone scans were repeated after treatment. New quantitative parameters were assessed and compared with markers of bone turnover and with skin temperature difference (STD).


RESULTS
Significant correlations between quantitative bone scan parameters and bone turnover markers were observed (all P < 0.05). These parameters decreased after treatment of CNO, and its reduction to the baseline value correlated with differences of bone turnover markers and STD (all P < 0.05).


CONCLUSIONS
Our study suggests that bone scanning can be used not only for diagnosis of CNO but also for monitoring disease activity by quantitative bone scan parameters.
Bem
Robert
R
Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. bemrob@yahoo.co.uk
Jirkovská
Alexandra
A
Dubsky
Michal
M
Fejfarová
Vladimira
V
Buncová
Marie
M
Skibová
Jelena
J
Jude
Edward B
EB
D000328:Adult; D000368:Aged; D001842:Bone and Bones / Q000000981:diagnostic imaging* / Q000378:metabolism; D048909:Diabetes Complications / Q000000981:diagnostic imaging; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000000981:diagnostic imaging; D005260:Female; D020233:Gait Disorders, Neurologic / Q000000981:diagnostic imaging*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010465:Perception; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D013669:Technetium Tc 99m Medronate; D014732:Vibration
D019275:Radiopharmaceuticals; D013669:Technetium Tc 99m Medronate